Celgene Corp. (CELG)

95.55
0.81 0.84
NASDAQ : Health Technology
Prev Close 96.36
Open 95.95
Day Low/High 95.37 / 96.27
52 Wk Low/High 58.59 / 97.07
Volume 2.52M
Avg Volume 8.73M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 67.88B
EPS 5.70
P/E Ratio 14.69
Div & Yield N.A. (N.A)
5 Reasons Why Celgene Should Buy Competitor Biogen

5 Reasons Why Celgene Should Buy Competitor Biogen

There are several reasons why Celgene should buy Biogen.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

A merger would be smart, profitable ... and attention-grabbing.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene executives have raised guidance for the year, but the stock retreated Monday.

JP Morgan Healthcare Conf.

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer breaks down why it is so difficult to buy drug stocks right now.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

My Takeaways and Observations (3:30 p.m. Edition)

The markets started the day like Usain Bolt at the start of a 100-meter race. But, unlike Bolt, the finish wasn't as strong as the start.   I thought one of the day's features was the reversal in bond yields, particularly after the good data.    The...

My Takeaways and Observations

"Who you tryin' to get crazy with, 'ese? Don't you know I'm loco?..." -- Cypress Hill, Insane in the Brain 2017 will be the year of "The Dude."    My favorite large-cap long Allergan  and short Caterpillar   for next year.  AGN closed up by $4(!) wh...

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

My Top Pick for 2017: Short QQQ

My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...

My Takeaways and Observations (3 p.m. Edition)

Is it Friday, yet? My annual tribute to "El Capitan."    Tech drek?!!!???!    Hope? Nope! (1) Part 1 (2) Part II (3) Part III   Palm Beach Chronicles (Issue #2 Supplement)    You know what I am shorting; here is what I am buying.    Stocks meandered...

My Takeaways and Observations

"Be true to your teeth so they won't be false to you." -- Soupy Sales Have we entered a post-fact investment world?    I moved to large ProShares UltraShort S&P500 ETF   position as my freak flags show again. Viva La Revolucion!    Good stuff from t...

My Takeaways and Observations

More of the same -- as Mr. Market remains enthusiastic with The Orange Swan and his contemplated policies aimed at catalyzing domestic economic growth.   But, with fear and doubt having left Wall Street, we may be reaching The Outer Limits. And I ha...

Expect Some Big-Cap Biotech Love in 2017

We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...

2 Biotech Giants Poised for a Better 2017

2 Biotech Giants Poised for a Better 2017

Here's why Gilead and Celgene should finally reward their shareholders next year.

My Takeaways and Observations

"Everyone here likes the bounce." -- President-elect Donald Trump (said in a meeting today at Trump Tower with tech executives) A good day for the ursine crowd but not so good for the bullish cabal as they had a bad day -- for a change. (Yes, I am w...

Cramer: Rate-Hike Silver Linings Playbook Gets Dusted Off

Cramer: Rate-Hike Silver Linings Playbook Gets Dusted Off

There's a reason why FANG is back -- though it never really went away.

Celgene Takes a Turn for the Better

Celgene Takes a Turn for the Better

Here's how we would get involved based on the charts.

My Takeaways and Observations

Was yesterday "FOMO" or something else?    I waited and then moved on the volatility trade.    "How many syllables Mario?" (A Putney Swope reference!)    Wall Street is now a fear-free zone.    Mark Hanson on negative homeowners' equity.    Shorted ...

I'm Buying Biotech on This Trump Scare

I'm Buying Biotech on This Trump Scare

If the market is going to overreact to every new missive from Trump, I plan to take advantage.

My Takeaways and Observations

"Well, they call you lady luck But there is room for doubt At times you have a very un-lady-like way Of running out..." -- Guys and Dolls, Luck Be A Lady (Frank Sinatra)  Trump will not likely Make Twitter Great Again.   I, bear.    Explaining my pr...

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.

My Takeaways and Observations

The important messages today are the developing divergences.    The strength in energy stocks (reflecting a $3.88 a barrel rise in crude oil) masked the underlying weakness in the broader markets. Stated simply, these divergences in breadth, highs/l...

My Takeaways and Observations (2 p.m. Edition)

"Takeaways" is early today as I have to prepare for two company meetings tomorrow morning.   I am seeing signs of some exhaustion after the vigorous two-week advance in the markets -- especially in the "league-leading" Russell Index. The Russell wil...

My Takeaways and Observations (3:30 p.m. Edition)

It may be time to embrace the contrary.    First issue (!!): The Palm Beach Chronicles.   My weekly (brief) technical review of the markets -- cooling off ahead?    BTIG's Stockton is bullish and so, as I have expressed, are most others!   Campbell ...

The Good, the Bad and the Ugly (2:30 PM Edition)

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

My Takeaways and Observations (2:30 p.m. Edition)

For now the run has been easy. But, from my perch, going forward it may not be as much fun, it wont be easy.    Changing leadership in a Trump world.    Trade of the Week -- shorted iShares Russell 2000 Index ETF at $131.50.    West Coast housing im...